Toxicity profile, antiplasmodial and gametocytocidal properties of Erigeron bonariensis L. (anc. Conyza bonariensis (L.) Cronquist).

ETHNOPHARMACOLOGICAL RELEVANCE: Erigeron bonariensis L. (anc. Conyza bonariensis (L.) Cronquist) is a medicinal plant with traditional use in Cameroonian folk medicine and other parts of Africa for the management of ailments, including malaria.

AIM: This study focused on investigating the antiplasmodial, gametocytocidal properties and toxicity profile of E. bonariensis.

MATERIALS AND

METHODS

Extracts of E. bonariensis were prepared by sequential maceration using n-hexane, ethyl acetate, and methanol, and their antiplasmodial properties were assessed on both sexual and asexual Plasmodium parasite stages. Additionally, cytotoxicity was assessed on the MDA-MB-231 breast cancer cell line, while acute and sub-chronic toxicity were evaluated using albino mice.

RESULTS

Generally, all extracts were active against both stages of the parasites at different levels. Hexane extract exhibited good antiplasmodial activity (IC50 6.02 ± 1.13 μg/mL) against asexual parasites while also demonstrating the highest gametocytocidal activity (IC50 1.863 ± 0.717 μg/mL). All extracts were relatively non-toxic on the MDA-MB-231 breast cancer cell line. No significant adverse effects at the tested dose were observed following an acute exposure with an LD50 > 5000 mg/kg BW. In the sub-chronic toxicity evaluation, no significant changes in body weight, or hematological and biochemical parameters were observed across the dosed groups compared to the control, with a p-value <0.05. Additionally, histopathological examination of the liver indicated no signs of toxicity or abnormalities.

CONCLUSION

The findings show that E. bonariensis has effective antiplasmodial and gametocytocidal properties in vitro and has relatively low toxicity. This study supports the use of E. bonariensis as a culturally appropriate alternative for malaria management. However, further studies are needed on the safety profile and in harnessing the therapeutic potential of E. bonariensis for the development of novel antimalarials.